Pretreatment TG/HDL-C ratio is superior to triacylglycerol level as an independent prognostic factor for the survival of triple negative breast cancer patients

Journal of Cancer

Volumn 7, Issue 12, 2016, Pages 1747-1754

  Dai, Danian ^a   Chen, Bo ^a   Wang, Bin ^b   Tang, Hailin ^a   Li, Xing ^a   Zhao, Zhiping ^c   Li, Xuan ^a   Xie, Xiaoming ^a   Wei, Weidong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Prognostic factor; TG; THR; TNBC; Triple negative breast cancer

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD ANALYSIS EQUIPMENT; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PREDICTIVE VALUE; PREMEDICATION; TRIACYLGLYCEROL BLOOD LEVEL; TRIPLE NEGATIVE BREAST CANCER;

EID: 85008465322     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.15776     Document Type: Article

References (40)

1. Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. American journal of cancer research. 2015; 5: 2929-43.
2. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109: 1721-8.
3. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast cancer research: BCR. 2006; 8: R66.
4. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007; 110: 876-84.
5. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13: 4429-34.
6. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24: 5652-7.
7. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC cancer. 2007; 7: 134.
8. Zhong Z, Shan M, Wang J, Liu T, Shi Q, Pang D. Decreased Wnt5a Expression is a Poor Prognostic Factor in Triple-Negative Breast Cancer. Medical science monitor: international medical journal of experimental and clinical research. 2016; 22: 1-7.
9. Jia W, Wu J, Jia H, Yang Y, Zhang X, Chen K, et al. The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients. PloS one. 2015; 10: e0143061.
10. Zhang Y, Dai J, McNamara KM, Bai B, Shi M, Chan MS, et al. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases. BMC cancer. 2015; 15: 699.
11. Silva FR, de Oliveira MG, Souza AS, Figueroa JN, Santos CS. Factors associated with malnutrition in hospitalized cancer patients: a croos-sectional study. Nutrition journal. 2015; 14: 123.
12. Akuyam A, Isah HS, Ogala WN. Serum lipid profile in malnourished Nigerian children in Zaria. The Nigerian postgraduate medical journal. 2008; 15: 192-6.
13. Liao F, He W, Jiang C, Yin C, Guo G, Chen X, et al. A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C. OncoTargets and therapy. 2015; 8: 3135-42.
14. Fan Y, Ding X, Wang J, Ma F, Yuan P, Li Q, et al. Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negative breast cancer but not non-TNBCs. The International journal of biological markers. 2015; 30: e200-7.
15. Cvetkovic Z, Cvetkovic B, Petrovic M, Ranic M, Debeljak-Martarcic J, Vucic V, et al. Lipid profile as a prognostic factor in cancer patients. Journal of BUON: official journal of the Balkan Union of Oncology. 2009; 14: 501-6.
16. Ni H, Liu H, Gao R. Serum Lipids and Breast Cancer Risk: A Meta-Analysis of Prospective Cohort Studies. PloS one. 2015; 10: e0142669.
17. Berrino F, Villarini A, Traina A, Bonanni B, Panico S, Mano MP, et al. Metabolic syndrome and breast cancer prognosis. Breast cancer research and treatment. 2014; 147: 159-65.
18. Rodrigues Dos Santos C, Fonseca I, Dias S, Mendes de Almeida JC. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC cancer. 2014; 14: 132.
19. His M, Zelek L, Deschasaux M, Pouchieu C, Kesse-Guyot E, Hercberg S, et al. Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. European journal of epidemiology. 2014; 29: 119-32.
20. Yadav BS, Chanana P, Jhamb S. Biomarkers in triple negative breast cancer: A review. World journal of clinical oncology. 2015; 6: 252-63.
21. Andey T, Sudhakar G, Marepally S, Patel A, Banerjee R, Singh M. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation. Molecular pharmaceutics. 2015; 12: 1105-20.
22. Kim S, Lee Y, Koo JS. Differential expression of lipid metabolism-related proteins in different breast cancer subtypes. PloS one. 2015; 10: e0119473.
23. Bora K, Pathak MS, Borah P, Das D. Variation in Lipid Profile Across Different Patterns of Obesity-Observations from Guwahati, Assam. Journal of clinical and diagnostic research: JCDR. 2015; 9: OC17-21.
24. Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nature reviews Genetics. 2009; 10: 109-21.
25. Alexopoulos CG, Pournaras S, Vaslamatzis M, Avgerinos A, Raptis S. Changes in serum lipids and lipoproteins in cancer patients during chemotherapy. Cancer chemotherapy and pharmacology. 1992; 30: 412-6.
26. Yang MH, Rampal S, Sung J, Choi YH, Son HJ, Lee JH, et al. The association of serum lipids with colorectal adenomas. The American journal of gastroenterology. 2013; 108: 833-41.
27. Melvin JC, Seth D, Holmberg L, Garmo H, Hammar N, Jungner I, et al. Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012; 21: 1381-4.
28. Jiang JT, Xu N, Zhang XY, Wu CP. Lipids changes in liver cancer. Journal of Zhejiang University Science B. 2007; 8: 398-409.
29. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134: 703-7.
30. Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer research. 2010; 70: 8117-26.
31. Klemm S, Zimmermann S, Peschel C, Mak TW, Ruland J. Bcl10 and Malt1 control lysophosphatidic acid-induced NF-kappaB activation and cytokine production. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104: 134-8.
32. Bureau F, Vanderplasschen A, Jaspar F, Minner F, Pastoret PP, Merville MP, et al. Constitutive nuclear factor-kappaB activity preserves homeostasis of quiescent mature lymphocytes and granulocytes by controlling the expression of distinct Bcl-2 family proteins. Blood. 2002; 99: 3683-91.
33. Liu YL, Qian HX, Qin L, Zhou XJ, Zhang B, Chen X. [Association of serum lipid profile with distant metastasis in breast cancer patients]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2012; 34: 129-31.
34. Wulaningsih W, Vahdaninia M, Rowley M, Holmberg L, Garmo H, Malmstrom H, et al. Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis. BMC cancer. 2015; 15: 913.
35. Tamura T, Inagawa S, Hisakura K, Enomoto T, Ohkohchi N. Evaluation of serum high-density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients. Journal of gastroenterology and hepatology. 2012; 27: 1635-40.
36. Liu YL, Qian HX, Qin L, Zhou XJ, Zhang B. Serum LDL-C and LDL-C/HDL-C ratio are positively correlated to lymph node stages in males with colorectal cancer. Hepato-gastroenterology. 2011; 58: 383-7.
37. Chi PD, Liu W, Chen H, Zhang JP, Lin Y, Zheng X, et al. High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma. PloS one. 2014; 9: e91080.
38. Wang L, Chi PD, Chen H, Xiang J, Xia ZJ, Zhang YJ. Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35: 2141-9.
39. De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nature immunology. 2014; 15: 152-60.
40. Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010; 328: 1689-93.